Opzelura (Ruxolitinib Phosphate Cream) 1.5% X 60gm

Ruxolitinib, the active ingredient in Opzelura, works by selectively inhibiting JAK1 and JAK2 enzymes. These enzymes are part of the immune system's signaling pathways. By inhibiting them, Ruxolitinib reduces cytokine signaling and decreases inflammation in the skin, which helps alleviate symptoms of atopic dermatitis and vitiligo.

The typical dosage of Opzelura is a thin layer applied to the affected areas twice daily. The maximum dosage is one 60-gram tube per week or one 100-gram tube once every two weeks. The exact dosage and duration of treatment should be determined by a healthcare provider based on the patient's condition and response to the medication.

The safety of Opzelura during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using Opzelura if you are pregnant, planning to become pregnant, or breastfeeding.

To order Opzelura from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

Opzelura is a non-steroidal topical treatment that works by inhibiting specific immune system pathways. Unlike corticosteroids, which are commonly used for eczema, Opzelura does not carry the same risks of skin thinning or other steroid-related side effects. It is particularly beneficial for patients who do not respond to other topical therapies or cannot use them.

Opzelura should be stored below 25°C, kept in the original pack, and protected from moisture. It is important to follow the storage instructions provided by the manufacturer to ensure the medication remains effective and safe to use.

Opzelura is applied as a thin layer to the affected areas of the skin twice daily. It is important to wash your hands after applying the cream, unless you are applying it to your hands. Do not cover the treated area with a bandage or other wrap unless instructed by your healthcare provider.

The most serious risks associated with Opzelura include serious infections, such as tuberculosis and fungal or viral infections, and an increased risk of certain cancers, including lymphoma and lung cancer. Regular monitoring by a healthcare provider is essential to manage these risks.

Opzelura should not be used by individuals with active or serious infections, those who are immunocompromised, or those who are allergic to ruxolitinib or any of the other ingredients in the cream. It is also not recommended for use in children under 2 years of age for atopic dermatitis or under 12 years of age for vitiligo.